Evidence map›Paper›PMID 26041995›Full record

ReviewFrontiers in cellular neuroscience2015

An updated role of microRNA-124 in central nervous system disorders: a review.

Yang Sun, Zhu-Min Luo, Xiu-Ming Guo, Ding-Feng Su, Xia Liu

Abstract readReview
In one paragraph

Review in Frontiers in cellular neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

142 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. SerumInternational journal of molecular sciences · 2026
    Article
  6. Review
  7. Antisense oligonucleotide-mediated upregulation ofMolecular therapy. Nucleic acids · 2025
    Article
  8. Extracellular vesicle-based therapies for neurodegenerative diseases.NeuroImmune pharmacology and therapeutics · 2025
    Review
  9. Journal of biological rhythms · 2025
    Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review: Neuroprotective Nanocarriers in Glaucoma.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  20. mNature communications · 2024
    Article

82 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yang SunDepartment of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai China.
Zhu-Min LuoDepartment of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai China.
Xiu-Ming GuoDepartment of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai China.
Ding-Feng SuDepartment of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai China.
Xia LiuDepartment of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNA-124 (miR-124) is the most abundant miRNA in the brain. Biogenesis of miR-124 displays specific temporal and spatial profiles in various cell and tissue types and affects a broad spectrum of biological functions in the central nervous system (CNS). Recently, the link between dysregulation of miR-124 and CNS disorders, such as neurodegeneration, CNS stress, neuroimmune disorders, stroke, and brain tumors, has become evident. Here, we provide an overview of the specific molecular function of miR-124 in the CNS and a revealing insight for the therapeutic potential of miR-124 in the treatment of human CNS diseases.

Indexed as

brain developmentbrain tumorCNS disordersCNS stressmicroRNA-124neurodegradationneuroimmunitystroke

Identifiers

PMID26041995
PMCPMC4438253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.